The Journal of infection · 2026
Clinical characteristics, outcomes and molecular epidemiology of group B streptococcal disease in young infants in the Netherlands.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Groenveld Marleen A, Visser Douwe H, Brouwer Matthijs C, Jamrozy Dorota, van Sorge Nina M, Snoek Linde, van Kassel Merel N, van de Beek Diederik, Bijlsma Merijn W, NOGBS study group
Аннотация
OBJECTIVES: Group B streptococcus (GBS) disease remains a major cause of morbidity and mortality in young infants. We conducted a prospective multi-centre cohort study to evaluate clinical outcomes, molecular epidemiology, and coverage of potential maternal vaccines candidates in the Netherlands.
METHODS: Between January 1st, 2018, and December 31st, 2024, infants aged 0-89 days with culture-confirmed GBS sepsis or meningitis were identified through the Netherlands Reference Laboratory of Bacterial Meningitis. Clinical data, including GBS serotype, were collected for all cases.
RESULTS: We included 375 infants; 212 (57%) had early-onset disease (0-6 days) and 163 (43%) late-onset disease (7-89 days). Overall, 205 (55%) infants had sepsis, 78 (21%) definitive meningitis, and 92 (24%) probable meningitis. Complications occurred in 220 (59%) infants; 331 (88%) recovered without abnormalities at discharge. Mortality was 5%. Among mothers eligible for intrapartum antibiotic prophylaxis, 40% received prophylaxis. Serotype III was most common (57%), followed by Ia (17%) and V (8%). Serotype III was associated with meningitis and late-onset disease. Potential coverage was 96% for the GBS6 vaccine and 99% for GBS-AlpN.
CONCLUSIONS: GBS disease in young infants remains associated with high morbidity and mortality. Limited adherence to intrapartum antibiotic prophylaxis highlights prevention gaps and supports maternal GBS vaccination.
METHODS: Between January 1st, 2018, and December 31st, 2024, infants aged 0-89 days with culture-confirmed GBS sepsis or meningitis were identified through the Netherlands Reference Laboratory of Bacterial Meningitis. Clinical data, including GBS serotype, were collected for all cases.
RESULTS: We included 375 infants; 212 (57%) had early-onset disease (0-6 days) and 163 (43%) late-onset disease (7-89 days). Overall, 205 (55%) infants had sepsis, 78 (21%) definitive meningitis, and 92 (24%) probable meningitis. Complications occurred in 220 (59%) infants; 331 (88%) recovered without abnormalities at discharge. Mortality was 5%. Among mothers eligible for intrapartum antibiotic prophylaxis, 40% received prophylaxis. Serotype III was most common (57%), followed by Ia (17%) and V (8%). Serotype III was associated with meningitis and late-onset disease. Potential coverage was 96% for the GBS6 vaccine and 99% for GBS-AlpN.
CONCLUSIONS: GBS disease in young infants remains associated with high morbidity and mortality. Limited adherence to intrapartum antibiotic prophylaxis highlights prevention gaps and supports maternal GBS vaccination.